Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global OTC leader grows in China

This article was originally published in The Tan Sheet

Executive Summary

Japanese firm Taisho Pharmaceutical, an OTC manufacturer and a majority stakeholder of Chinese firm Shanghai Dazhengli Health Care, purchased the 15 percent of the firm held by the Guan Shen Yuan Group for 14.7994 million yuan ($2.2 million at Sept. 24 conversion rates). Taisho set up Shanghai Dazhengli Health Care in 1997 to sell its Libogen products in China. Shanghai Dazhengli can produce more than 20 million bottles of Lipovitan D nutrient drink annually. Taisho wants to expand its production and sales in China from Shanghai

Topics

UsernamePublicRestriction

Register

PS102144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel